Combination immunotherapy which neutralises the effects of TNFα and IL- 1β attenuates the circulatory failure and multiple organ dysfunction caused by endotoxin in the rat

Journal of Physiology and Pharmacology

Volumn 48, Issue 4, 1997, Pages 605-621

  Ruetten, H ^a   Thiemermann, C ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Combination immunotherapy; Cytokines; Endotoxemia; Interleukin 1; Multiple organ dysfunction; Multiple organ failure; Nitric oxide synthase; Septic shock; Tumour necrosis factor

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CYTOKINE; ENDOTOXIN; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA ANTIBODY; NITRIC OXIDE SYNTHASE; POLYCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG MIXTURE; ENDOTOXEMIA; ENZYME INDUCTION; ESCHERICHIA COLI; HYPOTENSION; INFLAMMATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER INJURY; MALE; MULTIPLE ORGAN FAILURE; NONHUMAN; PANCREAS INJURY; RAT; SEPTIC SHOCK;

ANIMALS; ANTIBODIES; BLOOD CIRCULATION; CELLS, CULTURED; ESCHERICHIA COLI; INTERLEUKIN-1; LIPOPOLYSACCHARIDES; MALE; MULTIPLE ORGAN FAILURE; MUSCLE, SMOOTH, VASCULAR; RATS; RATS, WISTAR; SHOCK, SEPTIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031457368     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (49)

1. Latini R, Bianchi M, Correale E et al. Cytokines in acute myocardial infarction: selective increase in circulating tumor necrosis factor, its soluble receptor, and interleukin-1 receptor antagonist. J Cardiovasc Pharmacol 1994; 23: 1-6.
2. McKenna RM, Macdonald C, Bernstein KN, Rush DN. Increased production of tumor necrosis factor activity by hemodialysis but not peritoneal dialysis patients. Nephron 1994; 67: 190-196.
3. Testa M, Yeh M, Lee P et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 1996; 28: 964-971.
4. Tracey KJ. Tumor necrosis factor (cachectin) in the biology of septic shock syndrome. Circ Shock 1991; 35: 123-128.
5. Billiau A, Vandekerckhove F. Cytokines and their interactions with other inflammatory mediators in the pathogenesis of sepsis and septic shock. Eur J Clin Invest 1991; 21: 559-573.
6. Okusawa S, Gelfand JA, Ikejima T, Connolly RJ, Dinarello CA. Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest 1988; 81: 1162-1172.
7. Dinarello CA. Cytokines as mediators in the pathogenesis of septic shock. Curr Topics Micobiol Immunol 1996; 216: 133-165.
8. Mozes TS, Ben-Efraim S, Tak CJ, Heiligers JP, Saxene R, Bonta IL. Serum levels of tumor necrosis factor determine the fatal or non-fatal course of endotoxic shock. Immunol Lett 1991; 27: 157-162.
9. Hewett JA, Jean PA, Kunkel SL, Roth RA. Relationship between tumor necrosis factor-alpha and neutrophils in endotoxin-induced liver injury. Am J Physiol 1993; 265: G1011-G1015.
10. Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985; 229: 869-871.
11. Fletcher DS, Agarwal L, Chapman KT et al. A synthetic inhibitor of interleukin-1 beta converting enzyme prevents endotoxin-induced interleukin-1 beta production in vitro and in vivo. J Interferon Cytokine Res 1995; 15: 243-248.
12. Ruetten H, Thiemermann C, Vane JR. Effects of the endothelin receptor antagonist, SB 209670, on circulatory failure and organ injury in endotoxic shock in the anaesthetized rat. Br J Pharmacol 1996; 118: 198-204.
13. Stuber F, Petersen M, Bokelmann F, Schade U. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. Crit Care Med 1996; 24: 381-384.
14. Friedland JS, Porter JC, Daryanani S et al. Plasma proinflammatory cytokine concentrations, Acute Physiology and Chronic Health Evaluation (APACHE) III scores and survival in patients in an intensive care unit. Crit Care Med 1996; 24: 1775-1781.
15. Tracey KJ, Fong Y, Hesse DG et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330: 662-664.
16. Wakabayashi G, Gelfand JA, Burke JF, Thompson RC, Dinarello CA. A specific receptor antagonist for interleukin 1 prevents Escherichia coli-induced shock in rabbits. FASEB J 1991; 5: 338-343.
17. Busse R, Mulsch A. Induction of nitric oxide synthase by cytokines in vascular smooth muscle cells. FEBS Lett 1990; 275: 87-90.
18. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002-2012.
19. Thiemermann C. The role of the L-arginine: nitric oxide pathway in circulatory shock. Adv Pharmacol 1994; 28: 45-79.
20. Szabo C, Thiemermann C. Regulation of the expression of the inducible isoform of nitric oxide synthase. Adv Pharmacol 1995; 34: 113-153.
21. Ruetten H, Southan GJ, Abate A, Thiemermann C. Attenuation of endotoxin-induced multiple organ dysfunction by 1-amino-2-hydroxy-guanidine, a potent inhibitor of inducible nitric oxide synthase. Br J Pharmacol 1996; 118: 261-270.
22. Deitsch EA. Multiple organ failure: pathophysiology and potential future therapy. Ann Surg 1992; 216: 117-134.
23. Bone R. Gram-positive organism and sepsis. Arch Intern Med 1994; 154: 26-34.
24. Green LC, Ruiz de Luzuriaga K, Wagner DA. Nitrate biosynthesis in man. Proc Natl Acad Sci USA 1981; 78: 7764-7768.
25. Bradford MM. A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
26. Hohlfeld T, Klemm P, Thiemermann C, Warner TD, Schror K, Vane JR. The contribution of tumour necrosis factor-alpha and endothelin-1 to the increase of coronary resistance in hearts from rats treated with endotoxin. Br J Pharmacol 1995; 116: 3309-3315.
27. Ruetten H, Thiemermann C, Vane JR. Effects of the endothelin receptor antagonist, SB 209670, on circulatory failure and organ injury in endotoxic shock in the anaesthetized rat. Br J Pharmacol 1996; 118: 198-204.
28. Thiemermann C, Vane JR. Inhibition of nitric oxide synthesis reduces the hypotension induced by bacterial lipopolysaccharide in the rat in vivo. Eur J Pharmacol 1990; 182: 591-595.
29. Szabo C, Mitchell JA, Thiemermann C, Vane JR. Nitric-oxide-mediated hyporeactivity to norepinephrine precedes the induction of nitric oxide synthase in endotoxin shock. Br J Pharmacol 1993; 108: 786-792.
30. Knowles RG, Merrett M, Salter M, Moncada S. Differential induction of brain, lung, and liver nitric oxide synthase by endotoxin in the rat. Biochem Biophys Res Commun 1990; 172: 1042-1048.
31. Rees DD, Cellek S, Palmer RM, Moncada S. Dexamrthasone prevents the induction by endotoxin of nitric oxide synthase and the associated effects on vascular tone: an insight into endotoxin shock. Biochem Biophys Res Commun 1990; 173: 541-547.
32. Thiemermann C, Wu CC, Szabo C, Perretti M, Vane JR. Tumour necrosis factor is an endogenous mediator of the induction of nitric oxide synthase in endotoxin shock. Br J Pharmacol 1993; 110: 177-182.
33. Szabo C, Wu CC, Gross SS, Vane JR. Interleukin-1 contributes to the induction of nitric oxide synthase by endotoxin in vivo. Eur J Pharmacol 1993: 250: 157-160.
34. Baue AE. The multiple organ or system failure syndrome. In Pathophysiology of Shock, Sepsis, and Organ Failure. G. Schlag and H. Redl (eds), Berlin: Springer Verlag; 1993. pp. 1004-1018.
35. Thiemermann C, Ruetten H, Wu CC, Vane JR. The multiple organ dysfunction syndrome caused by endotoxin in the rat: attenuation of liver dysfunction by inhibitors of nitric oxide synthase. Br J Pharmacol 1995; 116: 2845-2851.
36. Ruetten H, Southan, GJ, Abate A, Thiemermann C. Attenuation of endotoxin-induced multiple organ dysfunction by 1-amino-2-hydroxy-guanidine, a potent inhibitor of inducible nitric oxide synthase. Br J Pharmacol 1196; 118: 261-270.
37. Ruetten H, Thiemermann, C. Attenuation by calpain inhibitor I, an inhibitor of the proteolysis of IB, of the circulatory failure and multiple organ dysfunction caused by endotoxin in the rat. Br J Pharmacol 1997; in press.
38. Abraham E, Wunderink R, Silverman H et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter trial. TNF-alpha Mab Sepsis Study Group. JAMA 1995; 273: 934-941.
39. Dhainaut JF, Vincent JL, Richard C et al. CDP571, a humanized antibody to tumor necrosis factor-alpha safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group. Crit Care Med 1995; 23: 1461-1469.
40. Cohen J, Carlet J. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 1996; 24: 1431-1440.
41. Reinhart K, Wiegand-Lohnert C, Grimminger F et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multi-center, randomized, placebo-controlled, dose-ranging study. Crit. Care Med. 1996; 24: 733-742.
42. Fisher CJ, Agosti JM, Opal SM et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The soluble TNF Receptor Sepsis Study Group. New Engl J Med 1996; 334: 1697-1702.
43. Fisher CJ, Slotman GJ, Opal SM et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of the sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. The IL-1RA Sepsis Syndrome Study Group. Crit Care Med 1994; 22: 12-21.
44. Fisher CJ, Dhainaut JF, Opal SM et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994; 271: 1836-1843.
45. Fisher CJ, Opal SM, Lowry SF et al. Role of interleukin-1 and the therapeutic potential of interleukin-1 receptor antagonist. Circ Shock 1994; 44: 1-8.
46. Knaus WA, Harrell FE, LaBrecque JF et al. Use of predicted risk of mortality to evaluate the efficacy of anti-cytokine therapy in sepsis. The rhIL-1ra Phase III Sepsis Syndrome Study Group. Crit Care Med 1996; 24: 46-56.
47. Smith SR, Calzetta A, Bankowski J, Kenworthy-Bott L, Terminelli C. Lipopolysaccharide-induced cytokine production and mortality in mice treated with Corynebacterium parvum. J Leukoc Biol 1993; 54: 23-29.
48. Cross AS, Opal SM, Palardy JE, Bodmer MW, Sadoff JC. The efficacy of combination immunotherapy in experimental Pseudomonas sepsis. J Infect Dis 1993; 167: 112-118.
49. Opal SM, Cross AS, Jhung JW et al. Potential hazards of combination immunotherapy in the treatment of experimental septic shock. J Infect Dis 1996; 173: 1415-1421.